North America Hereditary Cancer Testing Market to 2027 - Regional Analysis and Forecasts by Diagnosis Type (Biopsy, Imaging); Technology (Sequencing, PCR, Microarray); End User (Hospital, Clinics, Diagnostic Centers), and Country
- THE3312646
- 132 Pages
- October 2019
- Diagnostic and Biotech
The growth of the hereditary cancer testing market is primarily attributed to increasing as increasing prevalence of hereditary cancer and growing awareness about hereditary cancer have been boosting the market over the years. On the other hand, favorable reimbursement scenario is expected to have a positive effect on the growth of the North America hereditary cancer testing market in the coming years.
Genetic testing helps evaluate the chance of developing cancer in a lifetime. The genetic testing is done by searching for specific mutations in genes, chromosomes, or proteins. An inherited gene mutation causes hereditary cancer. An inherited gene is the one which is passed from parent to child in a family. Various methods are used for hereditary cancer testing; it includes genetic counseling. The counseling provides a discussion regarding recommendations for preventive care and screening with the patient. They support groups and other information resources and provide emotional support to the person getting the results. The technological advances have allowed more significant integration of genomics into health care delivery, facilitating screening and molecular diagnostics along with the precise detection of microbes, and prescription and monitoring of efficiency of more accurate therapeutics. The growing demand for noninvasive method for cancer testing may stimulate market growth during the forecast period.
North America hereditary cancer testing market is segmented by diagnosis type, technology, and end user. On the basis of diagnosis type, the market is segmented into biopsy and imaging. On the basis of technology, the market is segmented into sequencing, PCR, and microarray. Based on end user, the market is segmented into diagnostic centers, hospital, and clinics. In 2018, the imaging held the largest share in the market, by diagnosis type.
Some of the major primary and secondary sources included in the report are, Food and Drug Administration, World Health Organization (WHO), Centers for Medicare & Medicaid Services (CMS), National Institute of Cancer Prevention and Research (NICPR), National Cancer Institute, Canadian Institutes of Health Research (CIHR) and others.
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
2. North America Hereditary Cancer Testing Market - Key Takeaways
3. North America Hereditary Cancer Testing Market - Market Landscape
3.1 Overview
3.2 Market Segmentation
3.2.1 Global Hereditary Cancer Testing Market - By Diagnosis Type
3.2.2 Global Hereditary Cancer Testing Market - By Technology
3.2.3 Global Hereditary Cancer Testing Market - By End User
3.2.4 North America Hereditary Cancer Testing Market - By Country
3.3 PEST Analysis
4. North America Hereditary Cancer Testing Market - Key Market Dynamics
4.1 Key Market Drivers
4.1.1 Favourable Reimbursement Scenario
4.1.2 Growing Awareness About Hereditary Cancer
4.2 Key Market Restraints
4.2.1 Gender Gap In Cancer Genetic Test
4.3 Key Market Opportunities
4.3.1 Whole Genome Sequencing (WGS) for Cancer
4.4 Future Trends
4.4.1 Demand For Personalized Medicines
4.5 Impact Analysis
5. Hereditary Cancer Testing Market - North America Analysis
5.1 North America Hereditary Cancer Testing Market Revenue Forecasts And Analysis
5.2 Performance of Key Players
6. North America Hereditary Cancer Testing Market Analysis - By Diagnosis Type
6.1 Overview
6.2 North America Hereditary Cancer Testing Market by Diagnosis Type, 2018 & 2027 (%)
6.3 North America Hereditary Cancer Testing Market Revenue And Forecasts To 2027, By Diagnosis Type (US$ Mn)
6.4 Biopsy Market
6.4.1 Overview
6.4.2 North America Biopsy Market Revenue and Forecasts to 2027 (US$ Mn)
6.4.3 Blood Sample Market
6.4.3.1 Overview
6.4.3.2 North America Blood Sample Market Revenue and Forecasts to 2027 (US$ Mn)
6.4.4 Cheek Swab Sample Market
6.4.4.1 Overview
6.4.4.2 North America Cheek Swab Sample Market Revenue and Forecasts to 2027 (US$ Mn)
6.5 Imaging Market
6.5.1 Overview
6.5.2 North America Imaging Market Revenue and Forecasts to 2027 (US$ Mn)
7. North America Hereditary Cancer Testing Market Analysis - By Technology
7.1 Overview
7.2 North America Hereditary Cancer Testing Market by Technology, 2018 & 2027 (%)
7.3 North America Hereditary Cancer Testing Market Revenue And Forecasts To 2027, By Technology (US$ Mn)
7.4 Sequencing Market
7.4.1 Overview
7.4.2 North America Sequencing Market Revenue and Forecasts to 2027 (US$ Mn)
7.5 Polymerase Chain Reaction (PCR) Market
7.5.1 Overview
7.5.2 North America Polymerase Chain Reaction (PCR) Market Revenue and Forecasts to 2027 (US$ Mn)
7.6 Microarray Market
7.6.1 Overview
7.6.2 North America Microarray Market Revenue and Forecasts to 2027 (US$ Mn)
8. North America Hereditary Cancer Testing Market Analysis - By End User
8.1 Overview
8.2 North America Hereditary Cancer Testing Market by End User, 2018 & 2027 (%)
8.3 North America Hereditary Cancer Testing Market Revenue And Forecasts To 2027, By End User (US$ Mn)
8.4 Diagnostic Centers Market
8.4.1 Overview
8.4.2 North America Diagnostic Centers Market Revenue and Forecasts to 2027 (US$ Mn)
8.5 Hospitals Market
8.5.1 Overview
8.5.2 North America Hospitals Market Revenue and Forecasts to 2027 (US$ Mn)
8.6 Clinics Market
8.6.1 Overview
8.6.2 North America Clinics Market Revenue and Forecasts to 2027 (US$ Mn)
9. North America Hereditary Cancer Testing Market Revenue and Forecasts to 2027
9.1.1 Overview
9.1.2 North America Hereditary Cancer Testing Market Revenue and Forecasts to 2027 (US$ Mn)
9.1.3 North America Hereditary Cancer Testing Market Revenue And Forecasts to 2027, By Diagnosis Type (US$ Mn)
9.1.3.1 North America Hereditary Cancer Testing Market Revenue And Forecasts To 2027, By Biopsy (US$ Mn)
9.1.4 North America Hereditary Cancer Testing Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
9.1.5 North America Hereditary Cancer Testing Market Revenue And Forecasts to 2027, By End User (US$ Mn)
9.1.6 North America Hereditary Cancer Testing Market Revenue and Forecasts to 2027, By Country (%)
9.1.7 US Hereditary Cancer Testing Market Revenue and Forecasts to 2027 (US$ Mn)
9.1.7.1 US Hereditary Cancer Testing Market Revenue and Forecasts to 2027 (US$ Mn)
9.1.7.2 US Hereditary Cancer Testing Market Revenue And Forecasts to 2027, By Diagnosis Type (US$ Mn)
9.1.7.2.1 US Hereditary Cancer Testing Market Revenue And Forecasts To 2027, By Biopsy (US$ Mn)
9.1.7.3 US Hereditary Cancer Testing Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
9.1.7.4 US Hereditary Cancer Testing Market Revenue And Forecasts to 2027, By End User (US$ Mn)
9.1.8 Canada Hereditary Cancer Testing Market Revenue and Forecasts to 2027 (US$ Mn)
9.1.8.1 Canada Hereditary Cancer Testing Market Revenue and Forecasts to 2027 (US$ Mn)
9.1.8.2 Canada Hereditary Cancer Testing Market Revenue And Forecasts to 2027, By Diagnosis Type (US$ Mn)
9.1.8.2.1 Canada Hereditary Cancer Testing Market Revenue And Forecasts To 2027, By Biopsy (US$ Mn)
9.1.8.3 Canada Hereditary Cancer Testing Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
9.1.8.4 Canada Hereditary Cancer Testing Market Revenue And Forecasts to 2027, By End User (US$ Mn)
9.1.9 Mexico Hereditary Cancer Testing Market Revenue and Forecasts to 2027 (US$ Mn)
9.1.9.1 Mexico Hereditary Cancer Testing Market Revenue and Forecasts to 2027 (US$ Mn)
9.1.9.2 Mexico Hereditary Cancer Testing Market Revenue And Forecasts to 2027, By Diagnosis Type (US$ Mn)
9.1.9.2.1 Mexico Hereditary Cancer Testing Market Revenue And Forecasts To 2027, By Biopsy (US$ Mn)
9.1.9.3 Mexico Hereditary Cancer Testing Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
9.1.9.4 Mexico Hereditary Cancer Testing Market Revenue And Forecasts to 2027, By End User (US$ Mn)
10. Hereditary Cancer Testing Market - Industry Landscape
10.1 Overview
10.2 Growth Strategies in the Hereditary Cancer Testing Market, 2016-2019
10.3 Organic Growth Strategies
10.3.1 Overview
10.3.2 Product Launch
10.3.3 Product Approval
10.3.4 Others
10.4 Inorganic Growth Strategies
10.4.1 Overview
10.4.2 Partnership
10.4.3 Agreement & Collaboration
10.4.4 Acquisition
11. Hereditary Cancer Testing Market-Key Company Profiles
11.1 Hologic Inc.
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Financial Overview
11.1.4 Product Portfolio
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Koninklijke Philips N.V.
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Financial Overview
11.2.4 Product Portfolio
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 Quest Diagnostics Incorporated
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Financial Overview
11.3.4 Product Portfolio
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 Myriad Genetics, Inc.
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Financial Overview
11.4.4 Product Portfolio
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Cancer Genetics Inc.
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Financial Overview
11.5.4 Product Portfolio
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Invitae Corporation
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Financial Overview
11.6.4 Product Portfolio
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 Myogenes
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Financial Overview
11.7.4 Product Portfolio
11.7.5 SWOT Analysis
11.7.6 Key Developments
11.8 Strand Life Sciences Pvt. Ltd.
11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Financial Overview
11.8.4 Product Portfolio
11.8.5 SWOT Analysis
11.8.6 Key Developments
11.9 Pathway Genomics Corporation
11.9.1 Key Facts
11.9.2 Business Description
11.9.3 Financial Overview
11.9.4 Product Portfolio
11.9.5 SWOT Analysis
11.9.6 Key Developments
11.10 CENTOGENE AG
11.10.1 Key Facts
11.10.2 Business Description
11.10.3 Financial Overview
11.10.4 Product Portfolio
11.10.5 SWOT Analysis
11.10.6 Key Developments
12. Appendix
12.1 About The Insight Partners
12.2 Glossary Of Terms
12.3 Methodology
12.3.1 Coverage
12.3.2 Secondary Research
12.3.3 Primary Research
Table 1. R&D Investments by Major Pharmaceutical Companies
Table 2. R&D Investments by PhRMA member companies,2016
Table 3. Number of Registered Studies for Clinical Trials
Table 4. Consolidation Across the CRO Industry
Table 5. North America Hereditary Cancer Testing Market Revenue And Forecasts To 2027, By Diagnosis Type (US$ Mn)
Table 6. North America Hereditary Cancer Testing Market Revenue And Forecasts To 2027, By Technology (US$ Mn)
Table 7. North America Hereditary Cancer Testing Market Revenue And Forecasts To 2027, By End User (US$ Mn)
Table 8. North America Hereditary Cancer Testing Market Revenue And Forecasts to 2027, By Diagnosis Type (US$ Mn)
Table 9. North America Hereditary Cancer Testing Market Revenue And Forecasts to 2027, By Biopsy (US$ Mn)
Table 10. North America Hereditary Cancer Testing Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
Table 11. North America Hereditary Cancer Testing Market Revenue And Forecasts to 2027, By End User (US$ Mn)
Table 12. US Hereditary Cancer Testing Market Revenue And Forecasts to 2027, By Diagnosis Type (US$ Mn)
Table 13. US Hereditary Cancer Testing Market Revenue And Forecasts to 2027, By Biopsy (US$ Mn)
Table 14. US Hereditary Cancer Testing Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
Table 15. US Hereditary Cancer Testing Market Revenue And Forecasts to 2027, By End User (US$ Mn)
Table 16. Canada Hereditary Cancer Testing Market Revenue And Forecasts to 2027, By Diagnosis Type (US$ Mn)
Table 17. Canada Hereditary Cancer Testing Market Revenue And Forecasts to 2027, By Biopsy (US$ Mn)
Table 18. Canada Hereditary Cancer Testing Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
Table 19. Canada Hereditary Cancer Testing Market Revenue And Forecasts to 2027, By End User (US$ Mn)
Table 20. Mexico Hereditary Cancer Testing Market Revenue And Forecasts to 2027, By Diagnosis Type (US$ Mn)
Table 21. Mexico Hereditary Cancer Testing Market Revenue And Forecasts to 2027, By Biopsy (US$ Mn)
Table 22. Mexico Hereditary Cancer Testing Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
Table 23. Mexico Hereditary Cancer Testing Market Revenue And Forecasts to 2027, By End User (US$ Mn)
Table 24. Recent Product Launch in the Hereditary Cancer Testing Market
Table 25. Recent Product Approval in the Hereditary Cancer Testing Market
Table 26. Recent Other Growth Strategies in the Hereditary Cancer Testing Market
Table 27. Partnerships in the Hereditary Cancer Testing Market
Table 28. Agreement & Collaboration in the Hereditary Cancer Testing Market
Table 29. Acquisitions in the Hereditary Cancer Testing Market
Table 30. Glossary of Terms, Hereditary Cancer Testing Management Market
Similar Reports
Biomaterials are materials of either synthetic or natural origin that are used for interaction with biological systems for medical purposes such as treating or repairing damage tissues. They are used in joint replacements, plastic surgeries, drug delivery devi...
- Publish Date: September 1, 2016
- $5370
The global DNA sequencing market was estimated to be $6,243 million in 2017 and is projected to reach $25,470 million in 2025 growing with a CAGR of 19% from 2018 to 2025. DNA sequencing is a type of technology in which several DNA strands can be sequenced through massive parallelization. The DNA sequencing contains both Sanger’s method of sequencing and non-Sanger’s methods of sequencing. ...
- Publish Date: May 24, 2017
- $5370
Patients with serious nervous system injuries or strokes often require lifelong assistance, which burdens patients, their families, and society. Innovative, paradigm shifting strategies are required to develop treatments for neurological injury. Early dia...
- Publish Date: May 24, 2017
- $5370
